



## Press Release

### **MSN Group Receives ANDA Approval for Dimethyl Fumarate Capsules**

**Hyderabad, 7th October 2020:** MSN Group (MSN), India's leading integrated pharmaceutical company, receives ANDA approval for Dimethyl Fumarate delayed release capsule. The active pharmaceutical ingredient as well as the finished formulation of Dimethyl Fumarate Delayed-Release Capsules are manufactured in-house at MSN's manufacturing facilities. MSN has entered into a commercial partnership with Dr Reddy's for marketing the product in the United States of America. The medicine will be available in strengths of 120 mg and 240 mg capsules in bottle count sizes of 14 and 60 capsules, respectively.

Dimethyl Fumarate is a prescription medicine used to treat relapsing forms of multiple sclerosis in Adults.

MSN currently has over 100 ANDAs & 710 DMFs and is world no 1 in Active US DMF Filings as per US FDA.